• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NTI 0.00% 5.7¢

NEUROTECH INTERNATIONAL LIMITED - Announcements

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) reports record revenue growth, European market expansion and strategic cost savings

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

NTI Appendix 2A26/03/21 download Created with Sketch. 300.04KB
NTI Appendix 2A19/03/21 download Created with Sketch. 300.17KB
NTI Appendix 2A15/03/21 download Created with Sketch. 223.6KB
NTI Proposed issue of Securities - NTI15/03/21 download Created with Sketch. 27.52KB
NTI Disclosure DocumentPRICE SENSITIVE15/03/21 download Created with Sketch. 401.87KB
NTI Proposed issue of Securities - NTI09/03/21 download Created with Sketch. 26.57KB
NTI Strategic Cultivation Partnership with CannaPacific09/03/21 download Created with Sketch. 111.61KB
NTI Notice of Expiry of Listed Options04/03/21 download Created with Sketch. 119.06KB
NTI Appendix 2A04/03/21 download Created with Sketch. 216.27KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 24.7KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 24.62KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 26.78KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 26.83KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 25.48KB
NTI Proposed issue of Securities - NTI02/03/21 download Created with Sketch. 25.23KB
NTI Neurotech Expands License with Dolce Cann GlobalPRICE SENSITIVE02/03/21 download Created with Sketch. 82.52KB
NTI Neurotech Secures $3.56m in FundingPRICE SENSITIVE02/03/21 download Created with Sketch. 165.7KB
NTI Appendix 4D and Half Year AccountsPRICE SENSITIVE26/02/21 download Created with Sketch. 661.89KB
NTI Trading HaltPRICE SENSITIVE26/02/21 download Created with Sketch. 173.33KB
NTI Phase One and Two Clinical Program Update15/02/21 download Created with Sketch. 122.56KB
NTI Quarterly Report and Appendix 4CPRICE SENSITIVE29/01/21 download Created with Sketch. 369.81KB
NTI Q&A with NTI Company Chairman, Brian Leedman20/01/21 download Created with Sketch. 111.38KB
NTI Change of Director's Interest Notice22/12/20 download Created with Sketch. 128.77KB
NTI Appendix 2A22/12/20 download Created with Sketch. 304.01KB
NTI Results of Meeting22/12/20 download Created with Sketch. 126.24KB
NTI Successful Completion of In Vitro StudiesPRICE SENSITIVE21/12/20 download Created with Sketch. 384.21KB
NTI Change of Director's Interest Notice x 317/12/20 download Created with Sketch. 459.43KB
NTI Update - Proposed issue of Securities - NTI17/12/20 download Created with Sketch. 32.41KB
NTI Update - Proposed issue of Securities - NTI17/12/20 download Created with Sketch. 28.02KB
NTI Disclosure DocumentPRICE SENSITIVE16/12/20 download Created with Sketch. 454.41KB
NTI Appendix 2A11/12/20 download Created with Sketch. 218.84KB
NTI Results of Meeting30/11/20 download Created with Sketch. 115.72KB
NTI Reinstatement to Official QuotationPRICE SENSITIVE30/11/20 download Created with Sketch. 402.35KB
NTI Further Success with Preliminary In-vitro StudiesPRICE SENSITIVE30/11/20 download Created with Sketch. 128.54KB
NTI Voluntary SuspensionPRICE SENSITIVE27/11/20 download Created with Sketch. 159.73KB
NTI Trading HaltPRICE SENSITIVE24/11/20 download Created with Sketch. 480.17KB
NTI Notice of General Meeting/Proxy Form23/11/20 download Created with Sketch. 898.36KB
NTI Initiation of Clinical Product Formulation Studies19/11/20 download Created with Sketch. 78.25KB
NTI Investor Presentation16/11/20 download Created with Sketch. 1.79MB
NTI Ceasing to be a substantial holder x213/11/20 download Created with Sketch. 231.84KB
NTI Appendix 2A12/11/20 download Created with Sketch. 215.5KB
NTI Quarterly Report and Appendix 4C - Additional Information12/11/20 download Created with Sketch. 67.89KB
NTI Disclosure DocumentPRICE SENSITIVE06/11/20 download Created with Sketch. 386.42KB
NTI Appendix 2A06/11/20 download Created with Sketch. 215.6KB
NTI Proposed issue of Securities - NTI02/11/20 download Created with Sketch. 28.49KB
NTI Proposed issue of Securities - NTI02/11/20 download Created with Sketch. 25.38KB
NTI Interim Results and Capital RaisingPRICE SENSITIVE02/11/20 download Created with Sketch. 103.57KB
NTI Quarterly Report and Appendix 4CPRICE SENSITIVE02/11/20 download Created with Sketch. 347.47KB
NTI Proposed issue of Securities - NTI29/10/20 download Created with Sketch. 32.63KB
NTI Notice of Annual General Meeting/Proxy Form29/10/20 download Created with Sketch. 1.02MB
NTI Trading HaltPRICE SENSITIVE29/10/20 download Created with Sketch. 143.63KB
NTI Response to ASX Price and Volume QueryPRICE SENSITIVE22/10/20 download Created with Sketch. 208.6KB
NTI Initial and Final Director's Interest Notices19/10/20 download Created with Sketch. 474.14KB
NTI Proposed issue of Securities - NTI19/10/20 download Created with Sketch. 30.44KB
NTI New Chairman Appointed19/10/20 download Created with Sketch. 71.88KB
NTI Change of Director's Interest Notice x 406/10/20 download Created with Sketch. 610.96KB
NTI Becoming a substantial holder02/10/20 download Created with Sketch. 39.17KB
NTI Completion of Acquisition30/09/20 download Created with Sketch. 70.15KB
NTI NTI Commences Landmark In Vitro Trials of Cannabis Strains23/09/20 download Created with Sketch. 78.36KB
NTI Ceasing to be a substantial holder10/09/20 download Created with Sketch. 12.09KB
NTI Completion of Placement07/09/20 download Created with Sketch. 63.07KB
NTI Neurotech Proceeds to in vitro trials after Positive ResultsPRICE SENSITIVE07/09/20 download Created with Sketch. 472.55KB
NTI Neurotech secures Brain Therapeutics as Greece distributor03/09/20 download Created with Sketch. 84.52KB
NTI Appendix 2A02/09/20 download Created with Sketch. 217.56KB
NTI Appendix 4E and Annual Report Updated31/08/20 download Created with Sketch. 731.36KB
NTI Appendix 4G31/08/20 download Created with Sketch. 387.97KB
NTI Appendix 4E and Annual ReportPRICE SENSITIVE31/08/20 download Created with Sketch. 718.09KB
NTI Results of Meeting31/08/20 download Created with Sketch. 90.89KB
NTI Disclosure DocumentPRICE SENSITIVE26/08/20 download Created with Sketch. 422.17KB
NTI Response to ASX price queryPRICE SENSITIVE21/08/20 download Created with Sketch. 657.35KB
NTI Pause in TradingPRICE SENSITIVE21/08/20 download Created with Sketch. 113.83KB
NTI Promising Early Results from Cannabinoid AnalysisPRICE SENSITIVE21/08/20 download Created with Sketch. 136.93KB
NTI Trading HaltPRICE SENSITIVE19/08/20 download Created with Sketch. 156.17KB
NTI Ceasing to be a substantial holder04/08/20 download Created with Sketch. 415.7KB
NTI Quarterly Report and Appendix 4CPRICE SENSITIVE30/07/20 download Created with Sketch. 453.14KB
NTI Notice of General Meeting/Proxy Form28/07/20 download Created with Sketch. 1.18MB
NTI Neurotech commences assays on Dolce cannabis strains27/07/20 download Created with Sketch. 191.21KB
NTI Appendix 2A22/07/20 download Created with Sketch. 214.78KB
NTI Disclosure DocumentPRICE SENSITIVE15/07/20 download Created with Sketch. 374.05KB
NTI Change in substantial holding15/07/20 download Created with Sketch. 124.48KB
NTI Proposed issue of Securities - NTI03/07/20 download Created with Sketch. 24.71KB
NTI Proposed issue of Securities - NTI03/07/20 download Created with Sketch. 38.63KB
NTI NTI Secures Option to Cannabis Strains Targeting AutismPRICE SENSITIVE03/07/20 download Created with Sketch. 143.12KB
NTI Trading HaltPRICE SENSITIVE01/07/20 download Created with Sketch. 328.64KB
NTI Reinstatement to Official QuotationPRICE SENSITIVE01/05/20 download Created with Sketch. 71.3KB
NTI Response to ASX Price and Volume QueryPRICE SENSITIVE01/05/20 download Created with Sketch. 241.53KB
NTI Quarterly Report and Appendix 4CPRICE SENSITIVE29/04/20 download Created with Sketch. 280.75KB
NTI Continued Suspension28/04/20 download Created with Sketch. 111.41KB
NTI Continued Suspension20/04/20 download Created with Sketch. 89.77KB
NTI Suspension from Official QuotationPRICE SENSITIVE14/04/20 download Created with Sketch. 183.29KB
NTI Becoming a substantial holder x409/04/20 download Created with Sketch. 5.7MB
NTI Mente receives CE Mark renewal for use with ASD ChildrenPRICE SENSITIVE09/04/20 download Created with Sketch. 170.22KB
NTI Trading HaltPRICE SENSITIVE08/04/20 download Created with Sketch. 213.23KB
NTI Pause In TradePRICE SENSITIVE08/04/20 download Created with Sketch. 115.74KB
NTI Appendix 3G06/04/20 download Created with Sketch. 279.99KB
NTI Secondary Trading Notice & Appendix 2A06/04/20 download Created with Sketch. 416.02KB
NTI Mente Continues to Build Awareness in Europe26/03/20 download Created with Sketch. 128.67KB
NTI Appendix 3G04/03/20 download Created with Sketch. 280.3KB
NTI Secondary Trading Notice & Appendix 2A04/03/20 download Created with Sketch. 368.73KB
NTI Appendix 4D & Half Year ReportPRICE SENSITIVE25/02/20 download Created with Sketch. 394.5KB
NTI Appendix 2A
26/03/21 download Created with Sketch. 300.04KB
NTI Appendix 2A
19/03/21 download Created with Sketch. 300.17KB
NTI Appendix 2A
15/03/21 download Created with Sketch. 223.6KB
NTI Proposed issue of Securities - NTI
15/03/21 download Created with Sketch. 27.52KB
NTI Disclosure Document
15/03/21PRICE SENSITIVE download Created with Sketch. 401.87KB
NTI Proposed issue of Securities - NTI
09/03/21 download Created with Sketch. 26.57KB
NTI Strategic Cultivation Partnership with CannaPacific
09/03/21 download Created with Sketch. 111.61KB
NTI Notice of Expiry of Listed Options
04/03/21 download Created with Sketch. 119.06KB
NTI Appendix 2A
04/03/21 download Created with Sketch. 216.27KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 24.7KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 24.62KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 26.78KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 26.83KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 25.48KB
NTI Proposed issue of Securities - NTI
02/03/21 download Created with Sketch. 25.23KB
NTI Neurotech Expands License with Dolce Cann Global
02/03/21PRICE SENSITIVE download Created with Sketch. 82.52KB
NTI Neurotech Secures $3.56m in Funding
02/03/21PRICE SENSITIVE download Created with Sketch. 165.7KB
NTI Appendix 4D and Half Year Accounts
26/02/21PRICE SENSITIVE download Created with Sketch. 661.89KB
NTI Trading Halt
26/02/21PRICE SENSITIVE download Created with Sketch. 173.33KB
NTI Phase One and Two Clinical Program Update
15/02/21 download Created with Sketch. 122.56KB
NTI Quarterly Report and Appendix 4C
29/01/21PRICE SENSITIVE download Created with Sketch. 369.81KB
NTI Q&A with NTI Company Chairman, Brian Leedman
20/01/21 download Created with Sketch. 111.38KB
NTI Change of Director's Interest Notice
22/12/20 download Created with Sketch. 128.77KB
NTI Appendix 2A
22/12/20 download Created with Sketch. 304.01KB
NTI Results of Meeting
22/12/20 download Created with Sketch. 126.24KB
NTI Successful Completion of In Vitro Studies
21/12/20PRICE SENSITIVE download Created with Sketch. 384.21KB
NTI Change of Director's Interest Notice x 3
17/12/20 download Created with Sketch. 459.43KB
NTI Update - Proposed issue of Securities - NTI
17/12/20 download Created with Sketch. 32.41KB
NTI Update - Proposed issue of Securities - NTI
17/12/20 download Created with Sketch. 28.02KB
NTI Disclosure Document
16/12/20PRICE SENSITIVE download Created with Sketch. 454.41KB
NTI Appendix 2A
11/12/20 download Created with Sketch. 218.84KB
NTI Results of Meeting
30/11/20 download Created with Sketch. 115.72KB
NTI Reinstatement to Official Quotation
30/11/20PRICE SENSITIVE download Created with Sketch. 402.35KB
NTI Further Success with Preliminary In-vitro Studies
30/11/20PRICE SENSITIVE download Created with Sketch. 128.54KB
NTI Voluntary Suspension
27/11/20PRICE SENSITIVE download Created with Sketch. 159.73KB
NTI Trading Halt
24/11/20PRICE SENSITIVE download Created with Sketch. 480.17KB
NTI Notice of General Meeting/Proxy Form
23/11/20 download Created with Sketch. 898.36KB
NTI Initiation of Clinical Product Formulation Studies
19/11/20 download Created with Sketch. 78.25KB
NTI Investor Presentation
16/11/20 download Created with Sketch. 1.79MB
NTI Ceasing to be a substantial holder x2
13/11/20 download Created with Sketch. 231.84KB
NTI Appendix 2A
12/11/20 download Created with Sketch. 215.5KB
NTI Quarterly Report and Appendix 4C - Additional Information
12/11/20 download Created with Sketch. 67.89KB
NTI Disclosure Document
06/11/20PRICE SENSITIVE download Created with Sketch. 386.42KB
NTI Appendix 2A
06/11/20 download Created with Sketch. 215.6KB
NTI Proposed issue of Securities - NTI
02/11/20 download Created with Sketch. 28.49KB
NTI Proposed issue of Securities - NTI
02/11/20 download Created with Sketch. 25.38KB
NTI Interim Results and Capital Raising
02/11/20PRICE SENSITIVE download Created with Sketch. 103.57KB
NTI Quarterly Report and Appendix 4C
02/11/20PRICE SENSITIVE download Created with Sketch. 347.47KB
NTI Proposed issue of Securities - NTI
29/10/20 download Created with Sketch. 32.63KB
NTI Notice of Annual General Meeting/Proxy Form
29/10/20 download Created with Sketch. 1.02MB
NTI Trading Halt
29/10/20PRICE SENSITIVE download Created with Sketch. 143.63KB
NTI Response to ASX Price and Volume Query
22/10/20PRICE SENSITIVE download Created with Sketch. 208.6KB
NTI Initial and Final Director's Interest Notices
19/10/20 download Created with Sketch. 474.14KB
NTI Proposed issue of Securities - NTI
19/10/20 download Created with Sketch. 30.44KB
NTI New Chairman Appointed
19/10/20 download Created with Sketch. 71.88KB
NTI Change of Director's Interest Notice x 4
06/10/20 download Created with Sketch. 610.96KB
NTI Becoming a substantial holder
02/10/20 download Created with Sketch. 39.17KB
NTI Completion of Acquisition
30/09/20 download Created with Sketch. 70.15KB
NTI NTI Commences Landmark In Vitro Trials of Cannabis Strains
23/09/20 download Created with Sketch. 78.36KB
NTI Ceasing to be a substantial holder
10/09/20 download Created with Sketch. 12.09KB
NTI Completion of Placement
07/09/20 download Created with Sketch. 63.07KB
NTI Neurotech Proceeds to in vitro trials after Positive Results
07/09/20PRICE SENSITIVE download Created with Sketch. 472.55KB
NTI Neurotech secures Brain Therapeutics as Greece distributor
03/09/20 download Created with Sketch. 84.52KB
NTI Appendix 2A
02/09/20 download Created with Sketch. 217.56KB
NTI Appendix 4E and Annual Report Updated
31/08/20 download Created with Sketch. 731.36KB
NTI Appendix 4G
31/08/20 download Created with Sketch. 387.97KB
NTI Appendix 4E and Annual Report
31/08/20PRICE SENSITIVE download Created with Sketch. 718.09KB
NTI Results of Meeting
31/08/20 download Created with Sketch. 90.89KB
NTI Disclosure Document
26/08/20PRICE SENSITIVE download Created with Sketch. 422.17KB
NTI Response to ASX price query
21/08/20PRICE SENSITIVE download Created with Sketch. 657.35KB
NTI Pause in Trading
21/08/20PRICE SENSITIVE download Created with Sketch. 113.83KB
NTI Promising Early Results from Cannabinoid Analysis
21/08/20PRICE SENSITIVE download Created with Sketch. 136.93KB
NTI Trading Halt
19/08/20PRICE SENSITIVE download Created with Sketch. 156.17KB
NTI Ceasing to be a substantial holder
04/08/20 download Created with Sketch. 415.7KB
NTI Quarterly Report and Appendix 4C
30/07/20PRICE SENSITIVE download Created with Sketch. 453.14KB
NTI Notice of General Meeting/Proxy Form
28/07/20 download Created with Sketch. 1.18MB
NTI Neurotech commences assays on Dolce cannabis strains
27/07/20 download Created with Sketch. 191.21KB
NTI Appendix 2A
22/07/20 download Created with Sketch. 214.78KB
NTI Disclosure Document
15/07/20PRICE SENSITIVE download Created with Sketch. 374.05KB
NTI Change in substantial holding
15/07/20 download Created with Sketch. 124.48KB
NTI Proposed issue of Securities - NTI
03/07/20 download Created with Sketch. 24.71KB
NTI Proposed issue of Securities - NTI
03/07/20 download Created with Sketch. 38.63KB
NTI NTI Secures Option to Cannabis Strains Targeting Autism
03/07/20PRICE SENSITIVE download Created with Sketch. 143.12KB
NTI Trading Halt
01/07/20PRICE SENSITIVE download Created with Sketch. 328.64KB
NTI Reinstatement to Official Quotation
01/05/20PRICE SENSITIVE download Created with Sketch. 71.3KB
NTI Response to ASX Price and Volume Query
01/05/20PRICE SENSITIVE download Created with Sketch. 241.53KB
NTI Quarterly Report and Appendix 4C
29/04/20PRICE SENSITIVE download Created with Sketch. 280.75KB
NTI Continued Suspension
28/04/20 download Created with Sketch. 111.41KB
NTI Continued Suspension
20/04/20 download Created with Sketch. 89.77KB
NTI Suspension from Official Quotation
14/04/20PRICE SENSITIVE download Created with Sketch. 183.29KB
NTI Becoming a substantial holder x4
09/04/20 download Created with Sketch. 5.7MB
NTI Mente receives CE Mark renewal for use with ASD Children
09/04/20PRICE SENSITIVE download Created with Sketch. 170.22KB
NTI Trading Halt
08/04/20PRICE SENSITIVE download Created with Sketch. 213.23KB
NTI Pause In Trade
08/04/20PRICE SENSITIVE download Created with Sketch. 115.74KB
NTI Appendix 3G
06/04/20 download Created with Sketch. 279.99KB
NTI Secondary Trading Notice & Appendix 2A
06/04/20 download Created with Sketch. 416.02KB
NTI Mente Continues to Build Awareness in Europe
26/03/20 download Created with Sketch. 128.67KB
NTI Appendix 3G
04/03/20 download Created with Sketch. 280.3KB
NTI Secondary Trading Notice & Appendix 2A
04/03/20 download Created with Sketch. 368.73KB
NTI Appendix 4D & Half Year Report
25/02/20PRICE SENSITIVE download Created with Sketch. 394.5KB
(20min delay)
Last
5.7¢
Change
0.000(0.00%)
Mkt cap ! $58.97M
Open High Low Value Volume
5.8¢ 5.8¢ 5.7¢ $705 12.36K

Buyers (Bids)

No. Vol. Price($)
1 150000 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 242746 3
View Market Depth
Last trade - 10.10am 01/11/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.